Table 3 Primary and secondary outcomes
Outcomes | Standard-dose meropenem (n = 38) | High-dose meropenem (n = 38) | P value |
|---|---|---|---|
Primary outcome | |||
Delta mSOFA score, median (IQR) | − 1 (− 6 to 3) | − 1 (− 9 to 4) | 0.746 |
Delta respiratory score | − 1 (− 3 to 2) | − 1 (− 4 to 2) | 0.136 |
Delta cardiovascular score | 0 (− 4 to 3) | − 1 (− 4 to 3) | 0.599 |
Delta liver score | 0 (− 1 to 2) | 0 (− 1 to 2) | 0.570 |
Delta renal score | 0 (− 1 to 2) | 0 (− 2 to 1) | 0.201 |
Delta coagulation score | 0 (− 2 to 3) | 0 (− 1 to 3) | 0.052 |
Secondary outcomes | |||
14-day mortality, n (%) | 6 (15.8) | 4 (10.5) | 0.736 |
28-day mortality, n (%) | 17 (44.7) | 13 (34.2) | 0.482 |
Clinical cure, n (%) | 33 (86.8) | 33 (86.8) | 1.000 |
Microbiological cure, n (%) | 17 (44.7) | 21 (55.3) | 0.492 |
Vasopressor-free days, median (IQR) | 24.5 (0–27) | 25 (0–27) | 0.350 |
Ventilator-free days, median (IQR) | 11.5 (0–24) | 10.0 (0–28) | 0.819 |
ICU-free days, median (IQR) | 0.5 (0–19) | 9.5 (0–20) | 0.819 |
Hospital-free days, median (IQR) | 0 (0–74) | 37.5 (0–72) | 0.819 |
Adverse events | |||
Diarrhea, n (%) | 12 (31.6) | 8 (21.1) | 0.435 |